Insights
Resources & News
Current perspectives on the biopharma go-to-market model
With increasing pressures on healthcare systems, the rise in power of different stakeholders such as payers, patients and policy makers, and the launch of highly specialised/rare treatments, such as personalised medicines, the traditional go-to-market models for...
A difficult journey: The pursuit of excellence in key account management
Historically, the pharma sector was able to focus oon demand generation after obtaining marketing authorisations for its drugs. But today, it is difficult to find the individual decision-maker who can make an autonomous decision given the widespread influence of...
Pan-European Specialty Pharma Business: Perfecting Your Game for Success in Europe
There was a time where regulatory process, promotional regulations and therapeutic guidelines were organized on a national basis. During the last 20 years, the EU has increasingly centralized and harmonized regulatory procedures and promotional practices; even access...
Dive in: Gaining long-term leadership in a therapy area can be commercially invaluable
Therapeutic area leadership was once defined simply by who had the biggest and best drug for that condition; the level of leadership could usually be measured by sales figures, but times have changed. Individual products are still undoubtedly the most important...
Five Steps to Find your ‘Beyond the Pill’ Strategy
Outcommes data are the holy grail of drug development and market access. Everyone involved in healthcare – physicians, patients, governments and in particular payers – wants to see incontestable proof that the introduction of a new drug will result in meaningful and...
Uptake challenges: Are healthcare systems ready for personalized medicines and companion diagnostics?
Although the number of personalised medicines is increasing, many countries are not set up to jointly assess both the medicine and its companion diagnostic, leading to lower reimbursement prices and slower product uptake. In some countries, patients do not even get...
2nd Global Medtech Industry Report: Accelerating Transformation for Success
Since publishing our first Global Medtech Industry Report, the healthcare environment has continued its rapid pace of change. The changing environment continues to hit the bottom-line of Medtech companies. Medtech executives have to cope with a multi-strategy world....
New shores: The shift from just selling pills to developing value-added services has only just begun
The case for ‘beyond the pill’ services is becoming well established. Most new drugs coming to market are perceived by some to have relatively limited value in their own right (eg incremental benefits over existing options). Some of the most urgent unmet needs in...
Making the Switch: Loyalty strategies are much easier to implement in the OTC segment making switching an attractive option for pharma
The pharmaceutical business model has been in transition for several years. Previously, unique positioning was achieved through clinical differentiation protected by a patent. Payers guaranteed reimbursement even if clinical profiles did not substantially differ from...
Insights
Weekly Free Business Resources
If you want to receive weekly business resources and news, please subscribe to our Insights blog.
Almasan AG
The right support for the pharma/ biotech, medtech/ diagnostics, life sciences and healthcare sectors at the right time in the right way: Advisory, Interim Management and Contracting/ Outsourcing.